1 -by-side in vitro FcgammaR-binding analyses,
cell-based ADCC assays, and in vivo IgG-mediated cellula
2 merged as a promising cell type for use as a
cell-based adjunct immunosuppressive therapy in solid or
3 B) and chimeric antigen receptor (CAR) for T-
cell-based adoptive cell transfer are among these develo
4 quantify agonist receptor selectivity, bias,
cell-based agonism, and the effects of receptor mutation
5 ombination of chemical, genetic, genomic and
cell-based analyses.
6 Using a combination of
cell-based and biophysical assays together with structur
7 Importantly, experimental validation with
cell-based and in vitro ATPase assays confirmed three (e
8 This involved biochemical,
cell-based,
and tier-one ADME techniques.
9 roach, a downscaled luciferase reporter gene
cell-based anti-AR-CALUX assay and LC-HRMS/MS nontarget
10 been hindered by the limitations of existing
cell based approaches.
11 Using
cell-based approaches and mouse models of Mtb infection,
12 f selected recent reports of stem/progenitor
cell-based approaches for retinal disease, with interpre
13 Here, we combined biochemical and
cell-based approaches to uncover a dual pathogenic mecha
14 l-based assay (1.5%), and in CSF controls by
cell-based assay (0.9%).
15 rum controls by tissue-based assay (0.5%) or
cell-based assay (1.5%), and in CSF controls by cell-bas
16 cosylation significantly decreased ADCC in a
cell-based assay and suppressed antibody-mediated cell k
17 Thereby a complete
cell-based assay for efficient drug screening is perform
18 We have established an NK-92
cell-based assay for IFN-gamma release, identified resid
19 hable kinases, we established an all-optical
cell-based assay for screening inhibitors, uncovered a d
20 g of the endogenous LGI4 transcript and in a
cell-based assay impaired the secretion of truncated LGI
21 Cell-based assay supports the physiological relevance of
22 Here we describe a reporter
cell-based assay to quantify inducible, replication-comp
23 assay, and selectively inhibited SOAT1 in a
cell-based assay using SOAT1-/SOAT2-CHO cells.
24 rse chemical structures was screened using a
cell-based assay.
25 ed phosphorylation of the EphA4 protein in a
cell-based assay.
26 Tau prions were measured using a
cell-based assay.
27 Together these data suggest that
cell based assays can reveal subtle but clinically relev
28 Cell based assays demonstrated that the optimized inhibi
29 it nanomolar potency in both biochemical and
cell based assays.
30 Cell-based assays also indicate that bVP24 exhibits decr
31 ve similarly to ZMC1 in both biophysical and
cell-based assays and are heretofore named ZMC2 (NSC3197
32 their biologic properties were determined in
cell-based assays and confocal microscopy.
33 annel blocking ability were determined using
cell-based assays and two-electrode voltage clamp (TEVC)
34 nterest in the HIV vaccine field but current
cell-based assays are usually difficult to reproduce acr
35 e National Cancer Center were analysed using
cell-based assays for MOG-IgG and aquaporin-4 immunoglob
36 excitotoxicity, hindering the development of
cell-based assays for NMDAR drug discovery.
37 with first-episode psychosis using classical
cell-based assays in three labs and a single molecule-ba
38 Biophysical analyses in combination with
cell-based assays indicate that hRpn13 binds preferentia
39 interacting ArfGAP 1) gene using functional
cell-based assays involving coexpression of GIT1 and PAK
40 In vitro and
cell-based assays revealed that the CNAbeta1-containing
41 Traditional methods rely on
cell-based assays that lack reproducibility and accuracy
42 Cell-based assays to assess the effect of ADH-41 on Abet
43 We tested all four TSCs in a number of
cell-based assays to examine mutant p53 reactivation and
44 We used surface plasmon resonance and
cell-based assays to investigate this important IFN-beta
45 However, some heterogeneity between
cell-based assays was clearly observed, highlighting the
46 nst norovirus 3C-like protease in enzyme and
cell-based assays was determined.
47 125)I-alphaDTX-labelled Kv1 subunits, and by
cell-based assays which expressed Kv1 subunits, LGI1 and
48 SHMT in target assays and PfNF54 strains in
cell-based assays with values in the low nanomolar range
49 AT3 with selectivity over STAT5 and STAT1 in
cell-based assays, and increases the apoptotic rate of c
50 itional repair function of NONO, revealed in
cell-based assays, could involve RNA interaction.
51 alidate mitoxantrone in orthogonal mammalian
cell-based assays, demonstrating that our screening appr
52 In recent years, in vitro
cell-based assays, ex vivo palate cultures, and genetica
53 mined the function of these structures using
cell-based assays, in vitro translation systems, and in
54 ryptic inhibited ligand signaling in various
cell-based assays, including SMAD-mediated luciferase re
55 Cell-based assays, like the cellular antioxidant activit
56 In CME and growth inhibition
cell-based assays, the data obtained was consistent with
57 y, which we demonstrate biochemically and in
cell-based assays.
58 characterized using different approaches and
cell-based assays.
59 t also apply to drug studies with other stem
cell-based assays.
60 zers, which was confirmed experimentally via
cell-based assays.
61 AP isoforms (alpha, varepsilon, or kappa) by
cell-based assays; and (3) clinical data available.
62 g interface was confirmed by a comprehensive
cell-based binding assay against a library of CTLA-4 mut
63 Based on these structures and complementary
cell-based,
biochemical, and molecular dynamics approach
64 expand the possibility of clinical in vitro
cell based biological assays for various pulmonary disea
65 bination of an organic drug synthesis with a
cell-based biological activity testing system, require a
66 Here we describe for the first time a
cell-based BLI (cBLI) application that allows label-free
67 ld-seeded cells is still a challenge in stem
cell-based bone regeneration.
68 on and that 25(OH)D3 has great potential for
cell-based bone tissue engineering.
69 Many promising targets for T-
cell-based cancer immunotherapies are self-antigens.
70 erapy for leukemia and new, more specific NK
cell-based cancer therapies.
71 This primary
cell-based co-culture system combined with microOCT imag
72 In
cell-based culture and brain metastasis models, we found
73 hibitors is a critical step for interpreting
cell-based data and guiding inhibitor optimization.
74 e, we present structural, spectroscopic, and
cell-based data supporting a novel copper-induced mechan
75 oscopy approach, multiplex immunofluorescent
cell-based detection of DNA, RNA and Protein (MICDDRP),
76 Stem
cell-based disease modeling is an emerging technology fo
77 ility of the developed solvent exchanger for
cell based downstream applications was proven.
78 This
cell-based driven SAR produced compounds with strong sin
79 Using chemical proteomics and an organotypic
cell-based drug screening assay, we determine the functi
80 Using a
cell-based drug-screening assay, we identified Acriflavi
81 As shown in
cell-based dual-luciferase reporter gene assays, functio
82 igens by FACS analysis and a newly developed
cell-based ELISA.
83 ation and for the future development of stem-
cell-based engineered T cell therapies.
84 As a result, it fills an urgent need for a
cell-based EPAC assay that can be conveniently performed
85 A reverse genetics
cell-based evaluation of genes linked to healthy human t
86 hese epidemics are replicated using a simple
cell-based experimental setup where the rate of evolutio
87 We developed a single
cell-based experimental system from Arabidopsis (Arabido
88 Confirming the
cell-based experiments, we found deficient LH3-specific
89 Studies of PORCN activity relied on
cell-based fatty acylation and signaling assays as no di
90 forced by protein-protein binding and single
cell-based flagellar motor switching analyses.
91 and tested as SGLT1/SGLT2 inhibitors using a
cell-based fluorescence assay of glucose uptake.
92 Cell-based fluorescence reporter assays in Escherichia c
93 ed libraries to find compounds that act on a
cell-based fluorescence sensor of ppGalNAc-T3 but not on
94 onfirmed through independent replication and
cell-based functional assays.
95 In combination with
cell-based functional studies, our data suggest that the
96 t two-hybrid (HT-eY2H) assay and a mammalian-
cell-based Gaussia princeps luciferase protein-fragment
97 In the field of dendritic
cell based genetic immunization, previously we showed th
98 d application of TGx-DDI for high-throughput
cell-based genotoxicity testing using nCounter technolog
99 Using a
cell-based GR activity assay that measures Dexamethasone
100 The
cell-based H2O2 generation is affected by the medium vol
101 5-bromo-2-methoxybenzyl) amine (ABMA) from a
cell-based high throughput screening for its capacity to
102 Here, through
cell-based high throughput screening we identified benza
103 ments are urgently required, however current
cell-based high-throughput screening (HTS) models to ide
104 ia against novel compounds isolated by whole-
cell-based high-throughput screening (HTS).
105 In this study, using a
cell-based high-throughput screening model representing
106 could activate multiple TLRs, we performed a
cell-based high-throughput screening of a small-molecule
107 To address this challenge, we employed a
cell-based,
high-throughput method using a luciferase re
108 Cell-based HRT (cHRT) is an alternative approach that ma
109 ously demonstrated lactational transfer of T
cell-based immunity from dam to foster pup.
110 Using
cell-based immunoprecipitation with plasma from cGVHD pa
111 eveloped a genetically adjuvanted, dendritic
cell-based immunotherapeutic for acute Chagas disease in
112 rofound implications in the development of T
cell-based immunotherapeutic strategies to treat blindin
113 In this study, we developed a CAR T
cell-based immunotherapeutic strategy to target TEM8, a
114 routine delivery of cell products, has made
cell-based immunotherapeutics a real prospect for cancer
115 nhibitors.Many patients fail to respond to T
cell based immunotherapies.
116 T
cell-based immunotherapies are a promising approach for
117 T-
cell-based immunotherapies are promising treatments for
118 n-presenting cells in current development as
cell-based immunotherapies, including Tol-DC, Rapa-DC, D
119 alter the vulnerability of cancer cells to T-
cell-based immunotherapies.
120 onserved mechanisms, which may explain why T-
cell-based immunotherapy can provide durable benefits wi
121 immune mechanisms and confer resistance to T-
cell-based immunotherapy.
122 into tumors, and enhanced the efficacy of T-
cell-based immunotherapy.
123 ould find sensible application in adoptive T
cell-based immunotherapy.
124 vocal radiologic complete regression after T-
cell-based immunotherapy.
125 For these studies, we created a novel,
cell-based in vivo system for study of wild-type and var
126 First: a new red-
cell-based index, Joint Indicator A, to discriminate bet
127 eration, the African spiny mouse, to examine
cell-based inflammation and tested the hypothesis that m
128 pment of compounds with potent enzymatic and
cell-based inhibition of LDH enzymatic activity.
129 t attribute to consider for obtaining potent
cell-based inhibition of this cancer metabolism target.
130 The structure-guided
cell-based inhibition studies further demonstrate that t
131 ulation devices have the potential to enable
cell-based insulin replacement therapies (such as human
132 In order for
cell-based insulin replacement to be applied as a treatm
133 will compromise the therapeutic potential of
cell-based insulin replacement.
134 ls from clinical trials, for stem/progenitor
cell-based interventions for retinal disease.
135 Stem/progenitor
cell-based interventions have the potential to address b
136 Preclinical studies suggest that
cell-based interventions may influence functional recove
137 Stem/progenitor
cell-based interventions represent a novel class of pote
138 m and long-term safety and efficacy of these
cell-based interventions.
139 Using
cell-based knockdown approaches and microarray analyses
140 Cell-based luciferase assays showed that the engineered
141 We propose a
cell-based mathematical model of tissue growth to invest
142 ication of off-target sites with independent
cell-based measurements of activity at those sites when
143 a showed that the rapidly deployed CX3CR1(+)
cell-based mechanism of immune exclusion is a defense me
144 In this report, the development of a
cell-based,
medium to high throughput screening assay th
145 Artificial and
cell-based membrane permeability assays provided evidenc
146 As compared to a
cell-based method, the described technique is rapid, qua
147 Using both biochemical and
cell-based methods to assess Galpha-RGS complex formatio
148 vered, and steady-state analysis followed by
cell-based microarray genome-wide model validation led t
149 onal tools to prioritize VUS and developed a
cell-based minigene splicing assay to confirm aberrant s
150 , ligand-copper complexes were examined in a
cell-based model and were found to prevent BoNT/A cleava
151 s) accumulated in LB-like inclusions in this
cell-based model as well as in a mouse model of LB disea
152 logues demonstrated inhibitory activity in a
cell-based model for SNAP-25 cleavage and an ex vivo ass
153 idene-N-retinylethanolamine elimination in a
cell-based model of macular degeneration.
154 In an in vitro and
cell-based model of MMP-dependent breast cancer cellular
155 Using a
cell-based model of pathogenic huntingtin expression, we
156 In an in vitro endothelial
cell-based model of the blood-brain barrier, we confirme
157 enetic regulators of PGRN levels in a rodent
cell-based model system.
158 re, the authors use a human pluripotent stem
cell-based model, termed the post-implantation amniotic
159 To this end a variety of
cell-based modelling approaches have been developed, ran
160 ability of an implementation of five popular
cell-based modelling approaches within a consistent comp
161 Mouse and
cell-based models demonstrate that commensal GPR119 agon
162 format and may be widely applied to in vitro
cell-based models in which matrix protein deposition ref
163 tenuates adipogenesis in various genetic and
cell-based models.
164 A
cell-based MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dipheny
165 865) were evaluated by tissue (n = 542) and
cell-based (
n = 323) assays.
166 etastatic tumors, especially when exploiting
cell-based nanotherapies.
167 -real-time, here we introduce a novel single-
cell based nanotool termed dual biomembrane force probe
168 tive CNS neurons, which is critical for stem
cell-based neural pathway regeneration.
169 ADH) is a possible hydride source inside the
cell based on studies using pyruvate as a cellular redox
170 mbrane-free enzymatic glucose/oxygen biofuel
cell based on transparent and nanostructured conducting
171 d outdoor stability testing of organic solar
cells based on a blend between a donor-acceptor polyfluo
172 em that controls the firing mode of thalamic
cells based on attentional demand.
173 system to recognize and eliminate malignant
cells based on differential antigen expression.
174 pathways and the AKT/FOXO1 pathway in immune
cells based on direct inhibition of Ubc13 enzymatic acti
175 effective manufacturing process for Si solar
cells based on electrodeposition.
176 ses can be manipulated in directing Abs or T
cells based on how efficiently the targeted Ag is endocy
177 further commercialization of thin-film solar
cells based on hybrid organohalide lead perovskites is i
178 Solar
cells based on hybrid perovskites have shown high effici
179 be the influence of CD27 and OX40 on human T
cells based on in vitro studies and on the phenotypes of
180 ingle-particle fusion in both fixed and live
cells based on loss of the mCherry signal.
181 drug sensitivity of single multiple myeloma
cells based on measuring their mass accumulation rate (M
182 tic separation (IMS) that typically enriches
cells based on one abundant marker.
183 ion between two photobioelectrochemical half-
cells based on photosystem 1 and photosystem 2 is invest
184 Solar-
cells based on Schottky junctions between metals and sem
185 mines the proliferation or quiescence of CRC
cells based on the absence or presence of SPDEF.
186 terneurons were discriminated from principal
cells based on the autocorrelogram, waveform parameters,
187 of a differential metabolic signature for BC
cells based on the BRCA1 functionality.
188 er dimension for NMR detection of biological
cells based on the cell type and corresponding particle
189 equires technology for measuring and sorting
cells based on the fluorescence levels before and after
190 ities have higher specificity to distinguish
cells based on the relative concentrations of their rece
191 measurement and selective sorting of single
cells based on the uptake of radiolabeled small molecule
192 f metagene entropy and allows the ranking of
cells based on their differentiation potential.
193 Solar
cells based on this new perovskite show power conversion
194 rotocol for laboratory scale (10 cm(2)) fuel
cells based on ultrasonic spray deposition of a standard
195 cursor, progenitor, and fully differentiated
cells) based on changes in stage-dependent combinations
196 We also propose how
cells, based on a signal-induced change in cytoplasmic p
197 NO in aqueous solution and in live RAW 264.7
cells, based on the soft nucleophilicity of the phosphin
198 screening strategy that outperforms existing
cell-based or biochemical approaches for identifying CRI
199 odels of the adult Drosophila midgut, a stem
cell-based organ with known resizing dynamics.
200 However, human
cell-based PanIN models with defined mutations are unava
201 g an isolated target protein or by utilizing
cell-based phenotypic assays.
202 ere we use an human-induced pluripotent stem
cell-based platform to demonstrate adverse impacts of ob
203 e the authors apply a human pluripotent stem
cell-based platform to study the effects of such compoun
204 Using a
cell-based prion propagation assay, we discovered that t
205 troporation methods for creating therapeutic
cell-based products are complex and expensive.
206 However, the use of
cell-based products derived from stem cells as therapeut
207 ries of studies to evaluate its in vitro and
cell-based properties.
208 Cell-based receptor binding assays confirm that Q8 is a
209 ntal biology, immunology, and embryonic stem
cell-based regenerative medicine.
210 f neuroprotection, gene replacement and stem
cell-based regenerative paradigms.
211 Using a
cell-based reporter assay, we screened C4a against a pan
212 ptor activation with low micromolar IC50s in
cell-based reporter assays, inhibit Gas6-inducible motil
213 We developed a
cell-based reporter system to quantitate pathogen-specif
214 ies on cells via variable-length tethers for
cell-based sandwich ELISA, therefore, provides a sensiti
215 By developing
cell-based SAR and using chemical proteomics, we identif
216 Using a high content
cell-based screen, we identified fibroblast growth facto
217 A discriminating
cell-based screening assay identified compound 001, whic
218 In a
cell-based screening of pleuromutilin derivatives agains
219 Our approach highlights the power of stem
cell-based screens and validation in human forebrain org
220 ent dCas9-TAD, named dCas9-TV, through plant
cell-based screens.
221 Here, we present multiplexed
cell-based sensors to simultaneously quantify stress ind
222 ould be a promising cell source for adoptive
cell-based SG therapies, and bioengineering of artificia
223 We then use a 3D
cell-based simulation with realistic cell-cell adhesion,
224 These findings present a
cell-based strategy that combines accelerated perfusion
225 Cell-based studies have identified several molecular tar
226 Cell-based studies indicate that PAGE4 interaction with
227 Cell-based studies revealed native-like signaling proper
228 Cell-based studies revealed that the synergy site is dis
229 he SDA complex coupled to enzyme kinetic and
cell-based studies to provide structure-function propert
230 Biochemical and
cell-based studies using both peptide and protein substr
231 In
cell-based studies, exon 7-associated variants shifted t
232 nant-negative GusR variants are validated in
cell-based studies.
233 RNA using an inducible human embryonic stem
cell-based system and microinjection of mouse zygotes.
234 y limits and thus difficult to achieve using
cell-based systems.
235 ted with disease states as well as assessing
cell-based targeting of effective therapeutic agents.
236 Next, we optimized a SH-SY5Y
cell based tauopathy model by introducing a novel 5-fold
237 ngineering improvements in either soluble or
cell-based TCRs for therapeutic purposes.
238 Here, we take advantage of newer stem
cell-based technologies to study the mechanisms by which
239 heart disease modeling, drug screening, and
cell-based therapeutic applications.
240 search efforts on the implementation of stem
cell-based therapeutic strategies in CHD.
241 tective compounds, and provide the basis for
cell-based therapeutic strategies.
242 g of natural gene circuits and the design of
cell-based therapeutic strategies.
243 properties ideally suit the requirements of
cell-based therapeutics, since they permit to characteri
244 vercoming many of the current limitations in
cell-based therapeutics.
245 iology to develop innovative engineered stem
cell-based therapeutics.
246 success of chimeric antigen receptor (CAR) T-
cell based therapies greatly rely on the capacity to ide
247 edical research models and for gene and stem
cell based therapies.
248 oth mechanistic studies and screening of new
cell based therapies.
249 Clinical trials of bone marrow
cell-based therapies after acute myocardial infarction (
250 ogramming, have shown enormous potential for
cell-based therapies against intractable diseases such a
251 associated with retinal diseases makes stem-
cell-based therapies an attractive strategy for personal
252 d cell manufacturing are poised to broaden T-
cell-based therapies and foster new applications in infe
253 ENS; information required for development of
cell-based therapies and models of enteric neuropathies.
254 RATIONALE:
Cell-based therapies are a promising option in patients
255 KEY POINTS: While autologous stem
cell-based therapies are currently being tested on elder
256 Although gene- and
cell-based therapies are on the horizon for RP and Usher
257 Cell-based therapies are promising alternative therapeut
258 Several
cell-based therapies are under pre-clinical and clinical
259 g has the potential to enable more-effective
cell-based therapies by using readily available cell sou
260 Recent studies have shown that stem
cell-based therapies can improve liver function in a mou
261 Stem
cell-based therapies for Parkinson's disease are moving
262 ion of cell behavior and offering customized
cell-based therapies for tissue engineering.
263 Although clinical studies have shown that
cell-based therapies improve wound healing, the recruitm
264 Cs may represent a promising alternative for
cell-based therapies in AD.
265 Replacing lost retinal cells via stem
cell-based therapies is an exciting, rapidly advancing a
266 Emerging research on
cell-based therapies is opening a new door for patients
267 tering A2AR antagonists concurrently with NK
cell-based therapies may heighten therapeutic benefits b
268 Moreover, clinical trials of
cell-based therapies present several unique methodologic
269 lls have emerged as potential candidates for
cell-based therapies to modulate the immune response in
270 We summarize here the status of
cell-based therapies to treat multiple sclerosis and mak
271 ating ARDS, including combination therapies,
cell-based therapies, and generic pharmacological compou
272 Cell-based therapies, including immunoablation followed
273 These developments, along with novel T
cell-based therapies, position us to expand the assortme
274 may impact future design of autologous stem
cell-based therapies.
275 tcomes in the treatment of lung disease with
cell-based therapies.
276 e potential role of cortical interneurons in
cell-based therapies.
277 olled trial) represents the largest study of
cell-based therapy for STEMI completed in the United Sta
278 using this method which may further lead to
cell-based therapy for treating corneal endothelial dysf
279 d feasibility of the clinical application of
cell-based therapy has been demonstrated, and promising
280 On the basis of several preclinical studies,
cell-based therapy has emerged as a potential new therap
281 ability, and efficacy of mesenchymal stromal
cell-based therapy in pilot clinical trials, including t
282 Of the various
cell-based therapy options, mesenchymal stem/stromal cel
283 elial stem cells for the development of stem
cell-based therapy or bioengineering SG tissues to repai
284 vide us with a strong basis for developing T
cell-based therapy targeting this shared neoepitope.
285 T cell adoptive transfer may be useful as a
cell-based therapy to improve the efficacy and safety of
286 These data suggest that to optimize TR1
cell-based therapy, IL-10 receptor expression has to be
287 tforms for disease study, drug screening and
cell-based therapy.
288 the use of hiPSC-CM for disease modeling and
cell-based therapy.
289 cells (MSCs) are a promising candidate for a
cell-based therapy.
290 has been a long-standing challenge for stem
cell-based tissue engineering.
291 ng for tissues, cell cultures, and even stem
cell-based tissue regeneration.
292 sly growing mouse incisor as a model of stem
cell-based tissue renewal, we found that the transcripti
293 gand-dependent LBD stabilization assays, and
cell-based transactivation measurements delineate struct
294 ficant step towards a new generation of stem
cell-based treatment for heart failure.
295 nts with a greater likelihood of response to
cell-based treatment.
296 ges in inputs and even predict the fate of a
cell based upon its signalling history and state.
297 ach capable of high throughput separation of
cells based upon surface molecule adhesion.
298 stant inflammation) and ineffectiveness of T-
cell-based vaccines against H pylori.
299 r elimination of latent HIV-1 infection by T
cell-based vaccines.
300 aimed toward the development of effective B
cell-based vaccines.